ReviewHerzschrittmachertherapie & Elektrophysiologie2021
Ablation therapy of postural orthostatic tachycardia syndrome, inappropriate sinus tachycardia and primary electrical diseases: new insights in invasive treatment options in severely symptomatic patients.
Review in Herzschrittmachertherapie & Elektrophysiologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving the goal management of some arrhythmic syndromes can be challenging; medical treatment for inappropriate sinus tachycardia (IST) and postural orthostatic tachycardia syndrome (POTS) may be ineffective, necessitating multidisciplinary team treatment. Implantable defibrillator devices (ICDs), along with anti-arrhythmic drugs (AADs), remain the first-line treatment for primary electrical diseases that pose a risk of sudden cardiac death (SCD). Ablation of the arrhythmogenic substrate is not always suggested in patients with these pathologies, but it may be a valuable support for reducing arrhythmic burden, improving quality of life, and treating pathologies that are resistant to pharmacological treatment; however, this option is not often considered due to the potential risks associated with an invasive approach. Minimally invasive hybrid ablation in these syndromes, such as a hybrid thoracoscopic approach and the use of non-invasive mapping systems, reduces post-surgery complications and ensures the best possible outcome for the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.